arrow
S

Sun Min Lim

Yonsei University
H指数:33
被引数:4,283

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study

皮下注射阿曼曲单抗在复发性/转移性头颈鳞状细胞癌中的应用:在免疫检查点抑制剂和化疗后疾病进展的患者中的初步结果,来自OrigAMI-4研究(1b/2期)

2025-11-220
OAAI
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-mutated Non-small Cell Lung Cancer: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study

皮下给药与静脉给药的Amivantamab(联合Lazertinib)在EGFR突变型非小细胞肺癌难治患者中的应用:PALOMA-3研究中的患者满意度与资源利用结果

2025-07-100
OA
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
2024-12-310
OAAI
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer
2024-10-210
OAAI
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types

探索芳香烃受体在肿瘤微环境中的表达和分布,重点是免疫细胞,在各种实体癌类型中

2024-04-121
OAAI
CD81 and CD82 in tumor infiltrating lymphocytes within the NSCLC tumor microenvironment play a crucial role in T cell activation and cytokine production
2024-03-220
PRE
CJRB-101 induces immune responses through the GUT-TME axis in immune cell-driven mechanism in lung cancer models
2024-03-220
PRE